Core One Labs Beheer

Beheer criteriumcontroles 2/4

De CEO Core One Labs is Joe Shacker, benoemd in Jul2020, heeft een ambtstermijn van 4.33 jaar. bezit rechtstreeks 0.6% van de aandelen van het bedrijf, ter waarde € 27.07K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.9 jaar en 3.6 jaar.

Belangrijke informatie

Joe Shacker

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.3yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	3.9yrs
Gemiddelde ambtstermijn bestuur	3.6yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Joe Shacker's beloning veranderd ten opzichte van Core One Labs's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2023	n/a	n/a	-CA$16m
Dec 31 2022	n/a	n/a	-CA$16m
Sep 30 2022	n/a	n/a	-CA$15m
Jun 30 2022	n/a	n/a	-CA$19m
Mar 31 2022	n/a	n/a	-CA$25m
Dec 31 2021	CA$243k	CA$120k	-CA$37m
Sep 30 2021	n/a	n/a	-CA$59m
Jun 30 2021	n/a	n/a	-CA$77m
Mar 31 2021	n/a	n/a	-CA$70m
Dec 31 2020	CA$60k	CA$60k	-CA$47m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Joe redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de German markt.

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Joe te vergelijken met de prestaties van het bedrijf.

CEO

Joe Shacker (33 yo)

4.3yrs

Tenure

CA$242,751

Compensatie

Mr. Joel Shacker also known as Joe, is Chief Executive Officer at Core One Labs Inc since July 3, 2020 and has been its Director since May 29, 2020. Mr. Shacker serves as Director at American Future Fuel C...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Joel Shacker	CEO & Director	4.3yrs	CA$242.75k	0.60% € 27.1k
Geoffrey Balderson	CFO, Secretary & Director	4.3yrs	CA$40.92k	0.079% € 3.5k
Santiago Ferro	Chief Medical Officer & Director	3.5yrs	CA$100.00k	0.89% € 40.0k
Brad Eckenweiler	Founder & Advisor	no data	geen gegevens	geen gegevens
Jan Burian	Chief Technical Officer	no data	geen gegevens	geen gegevens
Elizabeth Matthews	Head of Scientific & Regulatory Affairs	3.6yrs	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

46yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van LD6 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Joel Shacker	CEO & Director	4.5yrs	CA$242.75k	0.60% € 27.1k
Geoffrey Balderson	CFO, Secretary & Director	3.3yrs	CA$40.92k	0.079% € 3.5k
Santiago Ferro	Chief Medical Officer & Director	1.8yrs	CA$100.00k	0.89% € 40.0k
Patrick Morris	Independent Director	4.8yrs	geen gegevens	0.17% € 7.5k
Dan Polonenko	Member of Advisory Board	3.6yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

46yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van LD6 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Core One Labs Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Core One Labs Inc. Announces Management Changes

Core One Labs Inc., Annual General Meeting, Feb 08, 2023

Less than half of directors are independent

Core One Labs Inc. Announces Resignation of Ryan Hoggan from its Board of Directors

Less than half of directors are independent

Executive Chairman recently sold €55k worth of stock

Recent updates

New major risk - Financial data availability

Core One Labs Inc. announced that it expects to receive CAD 1.5 million in funding

New minor risk - Financial data availability

Core One Labs' Akome Reveals Impressive Results for Its Psychedelic Bio- Compounds Designed to Target Alzheimer's and Parkinson's, Showing Potential to Outperform Current Treatment Methods

New major risk - Market cap size

New major risk - Shareholder dilution

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it has received CAD 0.2 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One Labs Inc. announced that it expects to receive CAD 1 million in funding

Core One's Akome Reveals Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease

Full year 2023 earnings released: CA$0.49 loss per share (vs CA$1.40 loss in FY 2022)

Core One Labs Inc.'s Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease

Core One Labs Inc. Announces Management Changes

Core One Labs Inc. (CNSX:COOL) acquired GMP Drug Inc. for CAD 3.5 million.

Core One Labs Inc., Annual General Meeting, Feb 08, 2023

Core One Labs Inc. Prepares for Commercial Production of API-Grade Psilocybin

Less than half of directors are independent

Core One Labs Applauds New Study Supporting Psilocybin Psychedelic Drug Therapy May Help Treat Alcohol Addiction

Core One Labs Inc. Announces Resignation of Ryan Hoggan from its Board of Directors

Less than half of directors are independent

Core One Labs Inc. (CNSX:COOL) acquired Awakened Biosciences Inc.

Core One Labs Inc. Expects Imminent Breakthrough to Produce NMT, Precursor to DMT

Core One Labs Applauds Health Canada’s Amendments to Special Access Program, Allowing Physicians to Request Patient Access to Psychedelic Treatments

Core One Labs Inc. (CNSX:COOL) acquired New Path Laboratories Inc. for CAD 3.4 million.

Core One Labs Inc. (CNSX:COOL) acquired Frontier Mycology Corp. for CAD 7.5 million.

Executive Chairman recently sold €55k worth of stock

Chief Science Officer & Director John Sanderson has left the company

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Akome Biotech Ltd.

Core One Labs Inc. (CNSX:COOL) acquired Bluejay Mental Health Group Inc.

Core One Labs in Collaboration with KICT to Explore DMT Assisted Psychotherapy

Core One Labs Inc. and Vocan Biotechnologies Inc. Initiates First Strain Production for Biosynthetic Psilocybin

Executive Chairman recently sold €65k worth of stock

Core One Labs Inc. (CNSX:COOL) entered into a letter of intent to acquire Ketamine Infusion Centers of Texas, LLC for $0.2 million.

High Tower Capital, Inc. completed the acquisition of Certain Assets of Core One Labs Inc. (CNSX : COOL).

Core One Labs Announces Breakthrough in Solving Psilocybin Dosing Problems by Introducing Biosynthetic Psilocybin to Its Patented Thinstrip Delivery Method

Core One Labs Inc. Announces Board Changes

Core One Labs Inc. (CNSX:COOL) completed the acquisition of Vocan Biotechnologies Inc.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd